KR20220119428A - 복합제 - Google Patents

복합제 Download PDF

Info

Publication number
KR20220119428A
KR20220119428A KR1020227024839A KR20227024839A KR20220119428A KR 20220119428 A KR20220119428 A KR 20220119428A KR 1020227024839 A KR1020227024839 A KR 1020227024839A KR 20227024839 A KR20227024839 A KR 20227024839A KR 20220119428 A KR20220119428 A KR 20220119428A
Authority
KR
South Korea
Prior art keywords
cancer
optionally substituted
compound
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227024839A
Other languages
English (en)
Korean (ko)
Inventor
아흐메드 아브디 사마타르
지안후이 마
지알리 리
피터 친후아 후앙
사이 가자난 헥데
케빈 듀언 번커
페르난도 도네이트
Original Assignee
리커리엄 아이피 홀딩스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리커리엄 아이피 홀딩스, 엘엘씨 filed Critical 리커리엄 아이피 홀딩스, 엘엘씨
Publication of KR20220119428A publication Critical patent/KR20220119428A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
KR1020227024839A 2019-12-20 2020-12-16 복합제 Ceased KR20220119428A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962952042P 2019-12-20 2019-12-20
US62/952,042 2019-12-20
US202063009754P 2020-04-14 2020-04-14
US63/009,754 2020-04-14
PCT/US2020/065411 WO2021127046A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
KR20220119428A true KR20220119428A (ko) 2022-08-29

Family

ID=76478099

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227024839A Ceased KR20220119428A (ko) 2019-12-20 2020-12-16 복합제

Country Status (12)

Country Link
US (1) US20230042653A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069224A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023507799A (cg-RX-API-DMAC7.html)
KR (1) KR20220119428A (cg-RX-API-DMAC7.html)
CN (1) CN115103673A (cg-RX-API-DMAC7.html)
AU (1) AU2020408698A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012286A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165477A1 (cg-RX-API-DMAC7.html)
IL (1) IL294084A (cg-RX-API-DMAC7.html)
MX (1) MX2022007624A (cg-RX-API-DMAC7.html)
TW (1) TW202135810A (cg-RX-API-DMAC7.html)
WO (1) WO2021127046A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Msd株式会社 Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
CA2706946A1 (en) * 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
HRP20140821T1 (hr) * 2009-09-15 2014-10-10 Merck Sharp & Dohme Corp. Priprema kristalnih hemihidratnih oblika dihidropirazolopirimidinona
SMT201700595T1 (it) * 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
AU2016344040B2 (en) * 2015-11-01 2020-12-10 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
US11932650B2 (en) * 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
EP3712150B1 (en) * 2017-11-01 2024-06-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as wee1 inhibitor and applications thereof
JP2022543832A (ja) * 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤

Also Published As

Publication number Publication date
BR112022012286A2 (pt) 2022-08-30
EP4069224A4 (en) 2023-12-20
US20230042653A1 (en) 2023-02-09
JP2023507799A (ja) 2023-02-27
MX2022007624A (es) 2022-08-16
CA3165477A1 (en) 2021-06-24
TW202135810A (zh) 2021-10-01
CN115103673A (zh) 2022-09-23
IL294084A (en) 2022-08-01
AU2020408698A1 (en) 2022-07-14
EP4069224A1 (en) 2022-10-12
WO2021127046A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
KR20220119657A (ko) 조합
JP7794448B2 (ja) 組み合わせ
KR20220119419A (ko) 복합제
KR20220119420A (ko) 조합
KR20220119442A (ko) 조합
US20230042653A1 (en) Combinations
WO2021127042A1 (en) Combinations
KR20220119427A (ko) 조합
RU2845443C1 (ru) Комбинации
KR20220119418A (ko) 조합물
KR20230007360A (ko) 복합제

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601